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Background: Recently, ivacaftor, a CFTR-potentiator, has been shown to be effective and safe in patients with cystic ﬁbrosis carrying a G551D
mutation and moderately impaired lung function. The objective of this retrospective study was to assess efﬁcacy and safety of ivacaftor in severely
ill patients with at least one G551D mutation.
Methods: Data from 14 patients with a FEV1 b40% predicted who received ivacaftor on a “named patient program” base in Germany were
analyzed.
Results: One patient took ivacaftor at a lower than recommended dose due to abundant mucus and a feeling to “suffocate.” No additional severe
adverse events were reported. One further patient stopped ivacaftor due to lung transplantation, one due to perceived poor effectiveness, one due to
pregnancy, and one stopped standard therapy. The remaining patients took ivacaftor regularly and did not change other therapies. FEV1 increased
by more than 5 %predicted in 5 of the 14 patients from baseline (average FEV1 during the year prior to ivacaftor). On average, FEV1 increased
signiﬁcantly by 5.2 ± 5.6%predicted (p b 0.01). The relative improvement in FEV1 was 19.7 ± 22.1%.
Conclusion: Ivacaftor was effective in many patients with poor lung function. The response was, however, variable. Although the drug appeared
safe for most of these patients, increased bronchial secretions may warrant intensiﬁed physiotherapy and intravenous antibiotic treatment when
ivacaftor is initiated.
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Cystic fibrosis (CF) is a multi-organ disease with an autosomal
recessive inheritance. Despite intensive treatment, life expectancy
is reduced in most people with CF, and pulmonary disease con-
tributes most to morbidity and mortality.
The genetic basis for CF is mutations in a gene on chromosome
7 which codes for a CF transmembrane regulator (CFTR) chloride
channel. Some of these mutations lead to a gating defect of the
CFTR protein located in the apical membrane of epithelial cellsby Elsevier B.V. All rights reserved.
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potentiate CFTR function in several mutant gating defects [1]. In
people with CF and at least one G551D mutation, ivacaftor has
shown strong positive effects on pulmonary function and body
weight without severe adverse effects [2]. Based on these findings
in patients with forced expiratory volume in 1 second (FEV1)
between 40 and 90% and additional data from adults [3] and
children [4], ivacaftor has been approved for treating people with
CF and at least one G551D mutation 6 years and older in the
United States early in January 2012 [5] and also in Europe in July
2012 [6]. The approvals are not restricted with respect to
pulmonary function.
The data available so far might suggest a good efficacy of
ivacaftor also in severe lung disease, i.e. FEV1 b40%predicted.
However, patients with CF and a poor FEV1 were not assessed
during the studies cited above. Furthermore, there are no safety
data for patients with severe lung disease receiving the novel
therapy.
On a “named patient program” base, from December 2011
on ivacaftor was available for severely ill patients with CF, a
G551D mutation, and an FEV1 b40%predicted in Germany.
The objective of this retrospective study was to assess efficacy
and safety of ivacaftor in this population.
2. Methods
During regular meetings of German CF center physicians and
international conferences, CF centres in Germany caring for
patients who received ivacaftor on a named patient program basis
were identified. In September 2012 and April 2013, the centres
were asked to provide anonymous retrospective information on all
patients who were treated with ivacaftor within the named patient
program. The study was approved by the Ethics Committee of
the Medical Faculty in Wuerzburg/Germany (Reference number
77/12).
The data provided by the centres included descriptive data,
anthropometric information, pulmonary function measures,Table 1
Patients' characteristics at the first day of ivacaftor.
ID Gender Age
(years)
Colonization CFRD Weight
(kg)
1 Male 33 SA No 46
2 Female 21 PSA Yes 40
3 Male 23 PSA No 43
4 Female 36 PSA Yes 60
5 Female 31 PSA, SA, ASP No 52
6 Male 30 PSA No 67
7 Male 41 PSA No 71
8 Male 31 PSA, SA No 70
9 Male 38 PSA, SA No 54
10 Female 48 PSA Yes 48
11 Female 41 PSA Yes 63
12 Male 47 PSA Yes 64
13 Female 36 PSA Yes 54
14 Female 23 PSA No 50
Average (±SD) 34 ± 8 56 ± 10
SD — standard deviation; SA — Staphylococcus aureus; PSA — Pseudomonas
diabetes mellitus; n.a. — not available.blood chemistry, history of exacerbations, adverse events and
reported experience of the patients.
2.1. Data analysis
Pulmonary function data and lung volumes submitted in liters
were expressed in %predicted [7,8]. For each patient, data were
plotted to visualize the individual changes over time for the
400-days period before starting ivacaftor and the period until
ivacaftor was stopped for the first time or until no further
follow-up data were available. Changes in FEV1 (%predicted),
RV/TLC (%predicted) and body weight (kg) were calculated for
all patients. Since some patients had large variation in pulmonary
function prior to the start of ivacaftor, individual baselines were
calculated for each patient as average of all available data points
from that patient collected during the year prior to the start of
ivacaftor. The last measurement from each individual was used to
calculate the changes. Baseline data were compared to the last
measurement using paired t-tests. Statistically significant changes
were assumed at p b 0.05.
3. Results
In total, data of 14 patients became available who received
ivacaftor on a named patient basis in Germany. Patients'
characteristics at the first day of treatment with ivacaftor are
summarized in Table 1.
Patient 7 received ivacaftor only for about 8 weeks. Then he
underwent lung transplantation and died shortly thereafter. Patient
10 stopped ivacaftor after about 4 months of treatment because
no effect was observed. She died from advanced liver disease
2 months later. During the treatment with ivacaftor, there was no
elevation in AST, ALT or bilirubin, and prothrombin time
remained stable but prolonged around 22 s (international normal-
ized ratio: 1.7 to 1.8). Patient 12 developed a severe exacerbation
after starting ivacaftor requiring hospitalization. He had problems
to expectorate the mucus from his bronchi which was liquefied byHeight
(cm)
BMI
(kg/m2)
FEV1
(%predicted)
FVC
(%predicted)
RV/TLC
(%predicted)
168 16.3 26.9 52.4 244
160 16.0 24.4 40.6 284
172 14.5 18.7 33.5 330
163 22.6 19.3 38.2 n.a.
160 20.3 27.6 57.4 n.a.
162 25.5 33.4 58.1 n.a.
180 21.9 17.7 52.5 n.a.
179 21.8 26.4 60.6 n.a.
169 18.9 17,8 29.8 273
161 18.5 25.6 75.0 150
164 23.4 21.6 69.3 173
178 20.2 13.9 38.0 232
179 16.9 38.7 83.5 214
153 21.4 37.3 59.6 187
168 ± 9 19.9 ± 3.2 25.0 ± 7.5 53.5 ± 16.0 232 ± 58
aeruginosa; ASP — Aspergillus fumigatus; CFRD — cystic fibrosis-related
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drug after about 4 months of irregular intake. He subsequently
died from pulmonary disease. Patient 13 became pregnant despite
detailed written and oral information including signed consent
(by her and her husband) while on ivacaftor and had to stop the
treatment after 6 weeks. However, ivacaftor was restarted 2 weeks
prior to delivery since the pulmonary situation of the patient
became critical. The baby is apparently healthy so far. Patient 14
discontinued all standard treatment while on ivacaftor. She was
lost from follow-up after 8 weeks of ivacaftor treatment. All other
patients were on regular ivacaftor therapy until April 2013.
Mean follow-up time after the start of ivacaftor in the entire
group was 235 days (42–395 days).Fig. 1. Change in FEV1, body weight and RV/TLC in 14 patients after the start of
measurements obtained during the year prior to ivacaftor (“pre”) and the last measuFig. 1 depicts individual FEV1 and body weight courses
before and after starting ivacaftor. FEV1 increased bymore than 5
%predicted in 5 of the 14 patients. On average, a significant
increase from baseline to the last day of follow-up on ivacaftor
was observed (5.2 ± 5.6 %predicted; median 3.9; range −4.1 to
16.8 %predicted, p = 0.005). The relative change in FEV1 was
19.7 ± 22.1 % (median 14.3; range −25.2 to 58.3%). Body
weight increased in 7 of the 14 patients by more than 1 kg. The
increase in body weight averaged 2.1 ± 2.4 kg (median 1.1,
range −0.3 to 6.3 kg, p = 0.005). Residual volume divided by
total lung capacity (RV/TLC) was only available in 10 patients.
In these patients, RV/TLC decreased non-significantly by
12.2 ± 30.7 %predicted.ivacaftor (day 0). The graphs on the right display the average of all available
rement reported (“post”).
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FEV1 (Fig. 2) or baseline RV/TLC (data not shown). There also
was no significant association between the changes in body
weight and FEV1. However, a reduction in RV/TLC was
significantly correlated with an increase in FEV1 (Fig. 2).
3.1. Adverse events possibly associated with ivacaftor treatment
Three patients observed more secretions at the beginning of the
ivacaftor treatment, both in the bronchi and the nasal cavity. One
of these, patient 12, reported to “suffocate” from the secretions so
that an unscheduled intravenous antibiotic therapy was initiated.
Ultimately, the ivacaftor therapy had to be discontinued. With
time, the other two patients observed a decrease in secretions. One
additional patient complained about headache at the start of
ivacaftor which resolved with time. In one patient, abdominal pain
and worsening of pre-existing restless legs were reported. One
patient experienced an intermittent increase in serum bilirubin just
slightly above normal and another patient an intermittent increase
in liver enzymes (maximal AST b3 times the upper limit of
normal, maximal ALT b4 times the upper limit of normal) shortly
after the initiation of ivacaftor. Ivacaftor was continued and AST
and ALT normalized within 2 months. Except for the patient who
had to stop ivacaftor due to abundant secretions, no unscheduled
antibiotic therapy became necessary in any of the other 13 patients
after the start of ivacaftor.
3.2. Patients' impressions on the effects of ivacaftor
All 14 patients reported their impressions after starting
ivacaftor. Eight patients observed a better fitness shortly after
starting ivacaftor, five a reduction in secretions compared with
baseline and one an improved nasal breathing. Two patients
could reduce their pancreatic enzyme supplementation.
4. Discussion
In patients with severe lung disease carrying the G551D
mutation, ivacaftor induced a similar relative increase in FEV1
from baseline – on average 19.7% – to the improvementsFig. 2. Changes in FEV1 after the start of ivacaftor and its associates. A) There was no
was not significantly correlated with ΔFEV1. C) A decrease in RV/TLC was signifi
measurements.reported for patients with milder lung disease (17.2%; [2]).
However, the increase in FEV1 expressed in absolute percent of
predicted was only about 5.2% in our severely affected patients
and thus much lower than the 10.6% observed in patients with
an FEV1 between 40% and 90% predicted [2] or the nearly 10%
shown for patients with an FEV1 between 40% and 50%
predicted (supplemental appendix to Ref. [2]).
There are also some preliminary data on the effects of
ivacaftor in patients with a FEV1 b40% for comparison with our
findings. A case report of an adult patient with a FEV1 of 24
%predicted demonstrates that considerable improvement in
FEV1 is possible with ivacaftor [10]. Furthermore, eight patients
who participated in the controlled phase III trial on ivacaftor as
controls [2] and rolled over to the open label PERSIST study, had
a FEV1 of 34.5 ± 3.7 %predicted at the time they first received
ivacaftor [11]. These patients improved their FEV1 within
12 weeks of ivacaftor by 13.0 ± 10.5 %predicted and thus
much more than the 14 patients in our series. However, our
patients had a far lower FEV1 at baseline (mean: 25.0 ± 7.5
%predicted). It is, therefore, likely that severe lung damage may
limit the improvement in FEV1 associated with ivacaftor.
However, in our sample, FEV1 or RV/TLC at baseline, expressed
in percentage of predicted, could not predict the improvement in
FEV1 following the introduction of ivacaftor to the patients'
medication. Nevertheless, a reduction in RV/TLC with ivacaftor
was associated with an improvement in FEV1 indicating that the
effect of ivacaftor on FEV1 may – at least in part – be mediated
by effects on hyperinflation.
The weight gain following the start of ivacaftor treatment
(2.1 ± 2.4 kg) compared similarly to the case series reported by
Ramsey et al. (3.1 kg) [2], especially when differences between
the populations (pure adult vs. mixed adolescent and adult) are
taken into consideration.
There were several mainly non-serious adverse events
associated with ivacaftor treatment in our case series and similar
to those reported from the phase III trial (supplementary appendix
to Ref. [2]). However, the patient with the lowest FEV1 of about
14% predicted experienced major difficulties to clear the
secretions from the airways so that the dose of ivacaftor had to
be reduced and – later on – the drug had to be stopped. Thisassociation between baseline FEV1 andΔFEV1. B) The change in body weight
cantly associated with an increase in FEV1 in the 10 patients with RV and TLC
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liquification of sputum in people with very severe lung disease
may lead to clinical deterioration. Based on the early experience
with the above patient, some subsequent patients with severe lung
disease were hospitalized for intravenous antibiotic treatment and
intense physiotherapy prior to ivacaftor and for the first week
after the drug was started.
This study has several limitations. First, the retrospective data
collection does not allow for complete data with assessments
at certain time points. Furthermore, there is no “placebo” control
group. It may be speculated that the excitement associated with
the novel treatment could have stimulated a better adherence
to the other therapies, thereby leading to improvements in FEV1
and weight gain. However, our patients had severely impaired
pulmonary function so that treatment adherence was likely quite
good even before the start of ivacaftor. In addition, a possible
“placebo” effect is expected to wane with time. Our follow-up
data over up to 13 months show that the effects of ivacaftor were
not lost with time. In some patients, there was even a continuing
improvement in FEV1 over several months. Last but not least, the
number of patients for analyses in this study is limited so that the
average responses reported are susceptible to outliers. However,
to our knowledge we included all patients participating in the
named patient program in Germany and present the largest case
series on the effects of ivacaftor in severely ill patients so far.
In conclusion, ivacaftor was effective in improving FEV1 and
body weight in patients with poor lung function although response
was variable and absolute increase in FEV1 was lower than
reported in patients with better preserved lung function. Although
the drug appears safe for most of the severely ill patients, increased
bronchial secretions may warrant increased physiotherapy and
intravenous antibiotic treatment in these patients when ivacaftor is
initiated.
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